Attention: Business/Financial Editors

The Medipattern Corporation ("Medipattern") (TSX VENTURE:MKI), congratulates
authors Daniel Gurell, MD and Marc Prager, MD for their work comparing
Visualize:Vascular(TM) to Magnetic Resonance Angiography (MRA). Their study
shows that Visualize:Vascular's 3D luminal ultrasound visualization correlates
well with MRA in a paper slated for presentation this coming weekend during the
2012 annual meeting of the Society of Radiologists in Ultrasound (SRU), which is
a sub-committee of the American College of Radiology. The blinded study uses the
results of ultrasound scans from 100 consecutive carotid arteries. Qualifying
cases were further evaluated using MRA. Results were then compared between the
two technologies. A correlation of 99%, p less than .05 was found between the
two imaging technologies. The results are statistically significant. Angiography
is considered to be the gold standard in evaluating arterial integrity.


"Stroke is the leading cause of morbidity and the third leading cause of death.
The first line of defense is the basic ultrasound Carotid Duplex Exam (CDE). Yet
there are conditions when CDE is inhibited by artifacts, impacting results.
Sensitivity and specificity of CDE results are statistically improved when used
in conjunction with 3D Luminal Ultrasound Visualization (LUV), and may obviate
the need for unnecessary additional testing allowing diseased patients to move
more rapidly to definite therapy," commented Daniel Gurell, MD.


"We appreciate the effort of Dr. Gurell and Dr. Prager. Their efforts and
enthusiasm for this technology made it a pleasure to work with their team. They
provided a much needed opportunity to examine how our technology operated and
differentiated itself in a real clinical setting. The experience has been vital
to the development of our product," commented Jeff Collins, CEO of Medipattern.
"Medipattern congratulates the doctors and their staff for creating an exacting
head to head comparison of LUV and MRA. We appreciate all their efforts." 


About UDMI:

University Diagnostic Medical Imaging ("UDMI") was founded in 1986, inspired by
a vision of providing the best diagnostic imaging by experienced,
board-certified radiologists. UDMI was the first full-service diagnostic
radiology facility in the nation to earn all eight of the accreditations offered
by the American College of Radiology. Today, UDMI is still owned and operated by
radiologists who care about their patients and work collaboratively with doctors
of many varied specialties to achieve the best outcome for all patients. Over
the years, UDMI has built a reputation for excellence and professionalism. UDMI
is committed to keeping abreast of the technological advances in radiology and
to incorporating them into the practice. The physicians at UDMI intend to always
be at the forefront of the medical field. For more information, please visit
www.udmi.net.


About the Medipattern Corporation:

Medipattern(R) is an award-winning leader in the development and
commercialization of healthcare solutions that positively impact people's lives
through the prevention of disease and analysis of medical images and data.
Medipattern's Knowledge-based Informatics (MKI) platform enables delivery of
these streamlined solutions. Medipattern mHealth uses patented prevention
technologies to engage, coach and monitor people in achieving their personalized
goals. Medipattern iaHealth uses patented pattern recognition technology to
analyze medical data to aid medical practitioners in the assessment of disease
and critical anatomy. For more information, please visit the Company's website:
www.medipattern.com.


Medipattern(R) is registered trademarks of The Medipattern Corporation.
Visualize:Vascular(TM) is a registered trademark of Medipattern.


Forward-looking statements 

This document contains forward-looking statements relating to Medipattern's
performance, operations, or business environment. These statements are based on
what we believe are reasonable assumptions given currently available information
and our understanding of Medipattern's current activities. We have tried,
whenever possible, to identify these forward-looking statements using words such
as "anticipates," "believes," "estimates," "expects," "plans," "intends,"
"potential", and similar expressions. Forward-looking statements are not
guarantees of future performance and involve risks and uncertainties that are
difficult to predict or control. A number of factors could cause actual outcomes
and results to differ materially from those expressed in forward-looking
statements. These factors include but are not limited to those set forth in the
Company's corporate filings, (posted at www.sedar.com). These factors should be
considered carefully, and readers should not place undue reliance on
Medipattern's forward-looking statements. In addition, these forward-looking
statements relate to the date on which they are made. The Company disclaims any
intention or obligation to update or revise any forward-looking statements for
any reason. Readers should not rely on forward-looking statements.



FOR FURTHER INFORMATION PLEASE CONTACT: 
The Medipattern Corporation
Jeff Collins
CEO
(416) 744-0009 ext. 224
jcollins@medipattern.com


Spinnaker Capital Markets Inc.
Kevin O'Connor
(416) 962-3300 ext. 226
ko@spinnakercmi.com
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From May 2024 to Jun 2024 Click Here for more The Medipattern Corp. Charts.
The Medipattern Corp. (TSXV:MKI)
Historical Stock Chart
From Jun 2023 to Jun 2024 Click Here for more The Medipattern Corp. Charts.